CTLA4Ig: bridging the basic immunology with clinical application

Jeffrey A Bluestone; E William St Clair; Laurence A Turka

doi:10.1016/j.immuni.2006.03.001

CTLA4Ig: bridging the basic immunology with clinical application

Immunity. 2006 Mar;24(3):233-8. doi: 10.1016/j.immuni.2006.03.001.

Authors

Jeffrey A Bluestone¹, E William St Clair, Laurence A Turka

Affiliation

¹ Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA. jbluest@immunetolerance.org

PMID: 16546089
DOI: 10.1016/j.immuni.2006.03.001

Abstract

After a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside.

MeSH terms

Abatacept
Animals
CD28 Antigens / physiology
CD40 Ligand / physiology
Humans
Immunoconjugates / pharmacology
Immunoconjugates / therapeutic use*
Lymphocyte Activation / drug effects
T-Lymphocytes / drug effects
T-Lymphocytes / immunology

Substances

CD28 Antigens
Immunoconjugates
CD40 Ligand
Abatacept